US 11,752,190 B2
Modulators of complement activity
Steven James DeMarco, Boxford, MA (US); Michelle Denise Hoarty, Billerica, MA (US); Grace Victoria Parker, Somerville, MA (US); Alonso Ricardo, Winchester, MA (US); Sylvia Tobe, Winchester, MA (US); and Douglas A. Treco, Arlington, MA (US)
Assigned to Ra Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Ra Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Oct. 8, 2020, as Appl. No. 17/65,560.
Application 17/065,560 is a continuation of application No. 16/062,653, granted, now 10,835,574, previously published as PCT/US2016/065228, filed on Dec. 7, 2016.
Claims priority of provisional application 62/347,486, filed on Jun. 8, 2016.
Claims priority of provisional application 62/331,320, filed on May 3, 2016.
Claims priority of provisional application 62/268,360, filed on Dec. 16, 2015.
Prior Publication US 2021/0077572 A1, Mar. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/12 (2006.01); A61K 9/00 (2006.01); A61P 7/00 (2006.01); A61P 37/02 (2006.01)
CPC A61K 38/12 (2013.01) [A61K 9/0019 (2013.01); A61P 7/00 (2018.01); A61P 37/02 (2018.01)] 18 Claims
 
1. A pharmaceutical composition comprising
a C5 inhibitor polypeptide comprising the core amino acid sequence of SEQ ID NO: 1;
a salt; and
a buffering agent.